Participated · Equity · Dec 2025

Niobium Microsystems is a Dayton-based company developing specialized chips that bring fully homomorphic encryption (FHE) into practical commercial use. Its custom silicon architecture allows data to remain encrypted even while it is being processed, offering mathematically guaranteed privacy for customers handling sensitive information. Led by CEO Kevin Yoder, the firm is currently building a production-ready application-specific integrated circuit (ASIC) and enhancing supporting infrastructure for pilot integrations. With offices in Portland and San Francisco, Niobium plans to broaden ecosystem enablement so partners can more readily adopt FHE-based solutions. The company recently secured more than $23 million in fresh capital to finalize its production silicon design and bolster customer-facing capabilities. Although financial performance metrics such as revenue or user count were not disclosed, the size of the latest raise underscores investor confidence in the company’s technology roadmap.

Participated · Series B · Sep 2025

Mojo Vision pioneers a wafers-in, wafers-out micro-LED platform intended to enable massively parallel optical I/O for AI infrastructure. Its integrated approach combines advanced 300mm CMOS circuitry, GaN-on-silicon micro-LED emitters, silicon photodetectors, multicore fiber bundles, custom micro-lens arrays, and proprietary software and tools. The company says this architecture enables thousands of optical channels in a compact footprint, delivering high bandwidth density, low energy per bit, and built-in redundancy. Mojo Vision has framed its technology as relevant to terrestrial data centers as well as distributed and orbital computing architectures where power, weight, and scalability matter. The company is based in Cupertino, Calif., and recently completed a $75 million financing the prior August before securing the $17.5 million strategic investment from Future Ventures. Mojo Vision is collaborating with Marvell to develop high-density micro-LED connectivity solutions as it advances commercialization.

Led · Series A · Jan 2024

Clarametyx Biosciences is a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases. Its lead program, CMTX-101, is an investigational antibody therapy designed to rapidly destroy the pro-inflammatory structure of bacterial biofilms to enhance antibiotic and immune efficacy and is being developed in cystic fibrosis. CMTX-101 is in a Phase 1b/2a trial evaluating safety, tolerability, pharmacokinetics, immunogenicity and reduction of pulmonary Pseudomonas aeruginosa burden; an interim analysis of the first 21 participants met prespecified criteria to proceed. The company is also advancing an anti-biofilm vaccine, CMTX-301, in early development and is pursuing lead optimization toward a 2027 IND. Clarametyx has closed an upsized second tranche of its Series A financing from existing investors to support ongoing pipeline activities for both therapeutic and vaccine programs. The Phase 1b/2a study is on track for full enrollment by the end of 2025, and additional participants and sites will be added. The company is based in Columbus, Ohio. Clarametyx Biosciences develops a technology platform that targets bacterial biofilms to enable a more effective immune response and antibiotic interventions. The company is building a pipeline of immune-enabling therapies and vaccines for serious bacterial infections associated with biofilms, with a near-term focus on chronic respiratory diseases. Its lead programs include CMTX-101, currently in a trial for cystic fibrosis–related infections conducted in collaboration with the Cystic Fibrosis Foundation, and CMTX-301, a vaccine program recently funded by CARB-X. The company is clinical stage and led by CEO David Richards. Clarametyx intends to use new funding to accelerate the ongoing CMTX-101 trial and advance development of CMTX-301. The company is based in Columbus, OH. Clarametyx Biosciences is a clinical-stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with bacterial biofilms. Launched in 2020 to advance an antibody technology licensed from Nationwide Children’s Hospital, the platform is non-antibiotic and pathogen-agnostic, designed to target and remove universal structural elements within biofilms to induce rapid biofilm collapse. Its lead candidate, CMTX-101, is being developed as an adjunct to standard-of-care antibiotics to render bacteria vulnerable to immune or antibiotic intervention. The company is evaluating its anti-biofilm technology in both therapeutic and preventive settings and is building a pipeline with a near-term focus on challenging respiratory infections. Clarametyx has initiated a Phase 1b/2a trial in people with cystic fibrosis to assess safety, tolerability, PK, immunogenicity, reduction of pulmonary P. aeruginosa burden, and exploratory endpoints (ClinicalTrials.gov identifier NCT06159725). The recently completed $33 million Series A will fund accelerated pipeline work and expanded clinical evaluations; the company is based in Columbus, Ohio. Clarametyx Biosciences is developing a platform that targets the biofilm matrix to remove a universal, pathogen-agnostic target, collapsing the protective shield and rendering bacteria vulnerable to immune and antibiotic attack. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development with a first targeted indication of moderate-to-severe or hospital-acquired pneumonia. The company is advancing IND-enabling activities including a GLP toxicity study and Phase 1 material production, with plans to initiate first-in-human clinical trials later this year. Financially, Clarametyx has received earlier CARB-X awards in 2020 and 2021 and was recently awarded an additional $3.89 million in option funding to accelerate development of CMTX-101. Under the CARB-X agreement the company is eligible for one further funding option to support a first-in-human trial, contingent on milestone achievement and competitive positioning. Clarametyx is building a broader pipeline of immune-enabling therapies and vaccines for life-threatening infections associated with biofilms. Clarametyx Biosciences is a preclinical-stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent, biofilm-associated bacterial infections. Its platform is designed to precisely remove a universal, pathogen-agnostic target within the biofilm extracellular matrix, rapidly collapsing the protective shield and sensitizing bacteria to immune and antibiotic attack. The approach aims to enhance innate immune activity and sensitize a wide range of Gram-negative and Gram-positive pathogens to first-line and other antibiotics, enabling potential therapeutics and vaccines. Lead candidate CMTX-101 is a humanized monoclonal antibody in preclinical development for hospital-acquired, moderate-to-severe pneumonia to be co-administered with standard antibiotic regimens. Clarametyx was awarded up to $14.2 million from CARB-X to advance its platform through completion of a Phase 1 clinical study, with a $2.4M base period and three milestone-based options. The company is based in Columbus, Ohio and is building a pipeline of immune-enabling therapies and vaccines for life-threatening infections associated with biofilms.

Participated · Series C · Oct 2022

Genetesis develops the CardioFlux biomagnetic imaging platform that leverages magnetocardiography to provide rapid, noninvasive cardiac assessments without radiation, contrast, or exercise. CardioFlux was cleared by the FDA in 2019 and received FDA Breakthrough Device designation in December 2020. The system has been clinically investigated in hundreds of patients with suspected acute and chronic coronary syndromes and in patients with confirmed coronary microvascular dysfunction. Genetesis is completing primary enrollment in the ACCMED trial with participating centers including Cleveland Clinic, Ascension St. John, Wake Forest Baptist Health, and Beaumont Royal Oak Hospital. The company plans to use recent financing to obtain FDA De Novo approval, launch additional clinical trials, and commercialize its biomagnetic systems globally across a variety of care settings. Following the Series C close, total funding exceeds $40 million. Genetesis has developed the CardioFlux Magnetocardiograph (MCG) for chest pain, addressing a problem that causes eight million emergency department visits annually. CardioFlux enables physicians to measure and record the heart's magnetic fields in a few minutes. The system operates without ionizing radiation, without exercise protocols, and without the need for specialized room modifications. The technology has the potential to lower emergency department length of stay for chest pain patients. Financially, the company raised $9.2M in Series B financing that included strategic investments from TDK Ventures and an undisclosed Fortune 500 global healthcare company, alongside return investors CincyTech, Ohio Innovation Fund and Mark Cuban. The company also added Sajid Malhotra to its board. Genetesis develops biomagnetic imaging systems and proprietary software to detect ischemic cardiac tissue and enable rapid, noninvasive chest pain triage. Its CardioFlux system performs a passive 60–90 second scan with no radiation or exercise required. The company completed a 100-patient, double‑blinded clinical study at St. John Hospital and described the findings as encouraging, with plans to publish in peer‑reviewed journals. Genetesis aims to give clinicians an accurate, easy‑to‑operate tool that can reduce the need for invasive and lengthy testing. The company plans to build and install additional CardioFlux systems, launch new clinical trials, and prepare for commercial launch. Genetesis is based in Mason, Ohio and will preview its technology at the American College of Emergency Physicians and American Heart Association Scientific Sessions. Genetesis develops CardioFlux™, a medical device that provides accurate, noninvasive 3D mapping of the heart's electrical activity. The system is intended to diagnose, characterize, and guide treatment for myocardial ischemia, atrial fibrillation, ventricular tachycardia and other arrhythmias, offering more insight than a conventional ECG. The company presented data collected with the Mayo Clinic at the American Heart Association Scientific Sessions showing promising improvements in noninvasive detection of ischemia in high‑risk chest pain compared with existing ER tools. Genetesis was founded in Mason, Ohio in 2013 and now employs a team of ten. The company plans to use the funding to scale engineering, launch additional clinical studies, and seek FDA regulatory clearance. Investors and management also see potential to expand the CardioFlux platform beyond cardiac applications into markets such as magnetic brain imaging.

Participated · Series C · Jan 2022

Enable Injections is a Cincinnati, OH-based healthcare company focused on improving the patient treatment experience with its enFuse On-Body Delivery System (OBDS), which enables subcutaneous administration of large-volume drugs. The technology aims to replace lengthy intravenous infusions with a discreet, wearable device that patients can use outside clinical settings. To scale production, the company announced plans in February 2024 for a 90,000-square-foot Manufacturing Center of Excellence in Springdale, Ohio, alongside upgrades to its Evendale headquarters. Enable Injections closed a $215 million Series C round in January 2022 led by Magnetar Capital, with participation from Sanofi and other institutional and regional investors. In January 2026, Sanofi committed an additional $30 million, underscoring strategic support for the commercialization of enFuse. The new capital will be used to consolidate supply-chain capabilities and accelerate commercial growth. These funds position Enable Injections to advance toward full-scale manufacturing and market launch of its OBDS platform.